|
|
Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensu... |
|
|
Acute Myeloid Leukemia: Targeting Key Clinical Issues for Oncology Nurses
The landscape of AML treatment is evolving, and newer targeted agents may improve outcomes for selected subgroups of patients. Activity goal considerations for the nurse/NP when participating in this activity:
Treatment decision making with incorporation of cytogenetic and molecular testing
Considerations in the care of a patient receiving therapy for AML related to nursing care and side effect management
Psychosocial considerations and resources for a patient with AML
Oncology nurses an... |
|
|
Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden
Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and lead to poor quality of life. Fortunately, therapies are now available to treat the anemia associated ... |
|